Surmodics (SRDX) 10-Q 3 Aug 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jun. 30, 2017	Jul. 25, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Trading Symbol	SRDX
Entity Registrant Name	SURMODICS INC
Entity Central Index Key	924,717
Current Fiscal Year End Date	--09-30
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		13,109,961

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Sep. 30, 2016
Current Assets:
Cash and cash equivalents	$ 11,350	$ 24,987
Available-for-sale securities	32,360	21,954
Accounts receivable, net of allowance for doubtful accounts of $149 and $19 as of June 30, 2017 and September 30, 2016, respectively	6,994	6,869
Inventories, net	3,505	3,579
Income tax receivable	993	697
Prepaids and other	2,467	472
Total Current Assets	57,669	58,558
Property and equipment, net	22,250	19,601
Deferred tax assets	3,073	5,027
Intangible assets, net	21,230	22,525
Goodwill	26,791	26,555
Other assets	877	628
Total Assets	131,890	132,894
Current Liabilities:
Accounts payable	1,916	1,622
Accrued liabilities:
Compensation	3,182	5,418
Due to customers	156	881
Accrued other	1,210	1,109
Contingent consideration	925	925
Deferred revenue	155	180
Total Current Liabilities	7,544	10,135
Contingent consideration, less current portion	12,916	13,592
Deferred revenue, less current portion	245	188
Other long-term liabilities	1,836	2,146
Total Liabilities	22,541	26,061
Commitments and Contingencies (Note 15)
Stockholders’ Equity:
Series A Preferred stock- $.05 par value, 450,000 shares authorized; no shares issued and outstanding
Common stock- $.05 par value, 45,000,000 shares authorized; 13,110,273 and 13,208,443 shares issued and outstanding as of June 30, 2017 and September 30, 2016, respectively	656	660
Additional paid-in capital	5,005	6,754
Accumulated other comprehensive income	2,016	1,273
Retained earnings	101,672	98,146
Total Stockholders’ Equity	109,349	106,833
Total Liabilities and Stockholders’ Equity	$ 131,890	$ 132,894

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Sep. 30, 2016
Statement Of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 149	$ 19
Series A Preferred stock, par value	$ 0.05	$ 0.05
Series A Preferred stock, shares authorized	450,000	450,000
Series A Preferred stock, shares issued	0	0
Series A Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.05	$ 0.05
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	13,110,273	13,208,443
Common stock, shares outstanding	13,110,273	13,208,443

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue:
Product sales	$ 8,327	$ 7,512	$ 23,964	$ 22,866
Royalties and license fees	7,244	10,556	22,564	25,207
Research, development and other	2,219	1,904	6,526	5,139
Total revenue	17,790	19,972	53,054	53,212
Operating costs and expenses:
Product costs	2,914	2,777	8,104	8,069
Research and development	7,927	4,693	22,105	13,195
Selling, general and administrative	5,232	4,483	15,170	12,984
Acquired intangible asset amortization	603	806	1,790	1,940
Contingent consideration (gain) expense	(629)	555	(803)	1,056
Acquisition transaction, integration and other costs		61		3,192
Total operating costs and expenses	16,047	13,375	46,366	40,436
Operating income	1,743	6,597	6,688	12,776
Other (loss) income:
Investment income, net	104	19	274	37
Foreign exchange (loss) gain	(594)	234	(121)	(336)
Gain on strategic investment and other		10		371
Other (loss) income, net	(490)	263	153	72
Income before income taxes	1,253	6,860	6,841	12,848
Income tax provision	(533)	(2,926)	(3,315)	(5,440)
Net income	$ 720	$ 3,934	$ 3,526	$ 7,408
Basic net income per share	$ 0.05	$ 0.30	$ 0.27	$ 0.57
Diluted net income per share	$ 0.05	$ 0.30	$ 0.26	$ 0.56
Weighted average number of shares outstanding:
Basic	13,155	12,995	13,190	12,969
Diluted	13,385	13,284	13,404	13,203

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 720	$ 3,934	$ 3,526	$ 7,408
Other comprehensive income (loss):
Unrealized holding (losses) gains on available-for-sale securities, net of tax	(8)	(34)	42	(36)
Foreign currency translation adjustments	2,295	(809)	701	919
Other comprehensive income (loss)	2,287	(843)	743	883
Comprehensive income	$ 3,007	$ 3,091	$ 4,269	$ 8,291

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating Activities:
Net income	$ 3,526	$ 7,408
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	4,006	3,703
Stock-based compensation	2,620	2,729
Contingent consideration (gain) expense	(803)	1,033
Unrealized foreign exchange loss	127	336
Deferred taxes	1,954	(181)
Gain on sale of strategic investment		(377)
Provision for bad debts	128
Other	(1)	(15)
Change in operating assets and liabilities, net of acquisitions:
Accounts receivable	(243)	1,999
Inventories	88	(112)
Prepaids and other	(2,091)	45
Accounts payable and accrued liabilities	(1,129)	746
Income taxes	(558)	1,253
Deferred revenue	32
Net cash provided by operating activities	7,656	18,567
Investing Activities:
Purchases of property and equipment	(4,881)	(4,869)
Purchases of available-for-sale securities	(54,935)	(9,562)
Maturities of available-for-sale securities	44,571
Cash proceeds from sales of property and equipment		15
Cash received from sale of strategic investment		377
Payments for acquisitions, net of cash acquired		(25,054)
Net cash used in investing activities	(15,245)	(39,093)
Financing Activities:
Issuance of common stock	216	284
Payments for taxes related to net share settlement of equity awards	(2,128)	(371)
Repurchase of common stock	(4,046)
Payment of deferred financing costs	(96)
Payment of contingent consideration		(305)
Net cash used in financing activities	(6,054)	(392)
Effect of exchange rate changes on cash and cash equivalents	6	(14)
Net change in cash and cash equivalents	(13,637)	(20,932)
Cash and Cash Equivalents:
Beginning of period	24,987	55,588
End of period	11,350	34,656
Supplemental Information:
Cash paid for income taxes	1,889	4,313
Noncash transactions from investing and financing activities:
Acquisition of property and equipment on account	112	133
Issuance of performance shares, restricted and deferred stock units	$ 2,414	1,390
Creagh Medical Ltd and NorMedix Inc [Member]
Noncash transactions from investing and financing activities:
Contingent consideration and debt assumed in Creagh Medical and NorMedix transactions		$ 13,597

Basis of Presentation

Basis of Presentation	9 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S.”) (“GAAP”) and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, needed to fairly present the financial results of Surmodics, Inc. and subsidiaries (“Surmodics” or the “Company”) for the periods presented. These financial statements include some amounts that are based on management’s best estimates and judgments. These estimates may be adjusted as more information becomes available, and any adjustment could be significant. The impact of any change in estimates is included in the determination of net income in the period in which the change in estimate is identified. The results of operations for the three and nine months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the entire 2017 fiscal year. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited consolidated financial statements of the Company. These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the fiscal year ended September 30, 2016, and footnotes thereto included in the Company’s Form 10-K as filed with the SEC on December 2, 2016.

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
New Accounting Pronouncements	2. New Accounting Pronouncements Accounting Standards to be Implemented In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2014-09, Revenue from Contracts with Customers (ASC Topic 606) In February 2016, the FASB issued Accounting Standards Update ASU 2016-02, Leases (ASC Topic 842) In June 2016, the FASB issued ASU No 2016-13, Financial Instruments – Credit Losses (ASC Topic 326), Measurement of Credit Losses on Financial Statements In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment Accounting Standards Implemented In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (ASC Topic 718): Improvements to Employee Share-Based Payment Accounting As a result of the adoption, the Company records excess tax benefits and certain tax deficiencies as income tax expense or benefit in the condensed consolidated statements of income, whereas such excess tax benefits or tax deficiencies were previously recorded in additional paid-in capital. As this guidance was applied retroactively to the beginning of the fiscal year ended September 30, 2016, previously reported quarterly income tax and net income for interim periods therein were adjusted for the effects of the adoption. This resulted in adjustments to increase the income tax provision and decrease net income by less than $0.1 million for the three months ended June 30, 2016 and to reduce the income tax provision and increase net income by less than $0.1 million for the nine months ended June 30, 2016. The adoption of this ASU also resulted in a (reduction) increase in net income per basic and diluted share of less than ($0.01) per share and $0.01 per share, respectively, for the three and nine-month periods ended June 30, 2016 The newly adopted guidance also requires presentation of excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity Prior to the adoption of ASU No. 2016-09, cash flows resulting from the tax benefits generated by tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) were classified as financing cash flows. During the nine months ended June 30, 2016, the Company realized tax benefits from stock options resulting in approximately $0.1 million of gross excess tax benefits, which are included as a component of cash flows from operating activities in the accompanying condensed consolidated statements of cash flows. This amount was previously reported as a component of cash flows from financing activities, but has been reclassified to conform to current accounting guidance. No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.

Business Combinations

Business Combinations	9 Months Ended
	Jun. 30, 2017
Business Combinations [Abstract]
Business Combinations	3. Business Combinations For all business combinations, the Company records all assets and liabilities of the acquired business, including goodwill and other identified intangible assets, at their respective fair values as of the acquisition date. Contingent consideration, if any, is recognized at its fair value on the acquisition date and changes in fair value are recognized in earnings until settlement. Acquisition-related transaction costs are expensed as incurred. Creagh Medical Ltd. On November 20, 2015, the Company acquired 100% of the outstanding common shares and voting shares of Creagh Medical Ltd. (“Creagh Medical”) located in Ballinasloe, Ireland. The acquisition was financed with cash on hand and contingent seller financing. The Company acquired Creagh Medical for up to €30 million (approximately $32 million as of the acquisition date), including an upfront payment of €18 million (approximately $19.3 million as of the acquisition date), and up to €12 million (approximately $12.8 million as of the acquisition date) based on achievement of revenue and value-creating operational milestones through September 30, 2018. The payment of the milestones, if any, will occur in the quarter ending December 31, 2018. Total transaction, integration and other costs associated with the Creagh Medical acquisition aggregated $0.1 million and $2.7 million for the three and nine months ended June 30, 2016, respectively Creagh Medical designs and manufactures high-quality percutaneous transluminal angioplasty (“PTA”) balloon catheters. Since 2006, Creagh Medical has grown its technical and product capability with PTA products approved throughout the world, including Europe, the United States, and Japan. With these resources, the Company is uniquely positioned to offer a total solutions approach from product design and development through in-house extrusion, balloon forming, top-assembly and packaging and regulatory capabilities to approved products for exclusive distribution. The purchase price of Creagh Medical consisted of the following: (Dollars in thousands) Cash paid $ 18,449 Debt assumed 761 Contingent consideration 9,064 Total purchase price 28,274 Less cash and cash equivalents acquired (251 ) Total purchase price, net of cash acquired $ 28,023 The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the Creagh Medical acquisition: Fair Value (Dollars in thousands) Estimated Useful Life (In years) Current assets $ 896 N/A Property and equipment 634 1.0-10.0 Trade name 75 N/A Developed technology 1,787 7.0 In-process research and development 942 N/A Customer relationships 11,119 7.0-10.0 Other noncurrent assets 81 N/A Current liabilities (942 ) N/A Deferred tax liabilities (9 ) N/A Net assets acquired 14,583 Goodwill 13,440 N/A Total purchase price, net of cash acquired $ 28,023 The Creagh Medical goodwill, which is a result of acquiring and retaining the Creagh Medical existing workforce and expected synergies from integrating their business into the Company’s Medical Device segment, is not deductible for tax purposes. NorMedix, Inc. On January 8, 2016, the Company acquired 100% of the shares of NorMedix, Inc. (“NorMedix”), a privately owned design and development company focused on ultra thin-walled, minimally invasive catheter technologies based in Plymouth, Minnesota. The acquisition was financed with cash on hand and contingent seller financing. The Company acquired NorMedix for up to $14.0 million, including an upfront payment of $7.0 million, and up to $7.0 million based on achievement of revenue and value-creating operational milestones through September 30, 2019. Contingent consideration associated with the NorMedix transaction is payable as earned. This acquisition strengthened the Company’s vascular device expertise and Research and Development (“R&D”) capabilities and was a significant component of the Company’s strategy to offer whole-product solutions to medical device customers, while continuing its commitment to consistently deliver innovation in coating technologies. Total transaction, integration and other costs associated with the NorMedix acquisition aggregated $0.0 million and $0.3 million for the three and nine-month periods ended June 30, 2016, respectively The purchase price of NorMedix consisted of the following: (Dollars in thousands) Cash paid $ 6,905 Contingent consideration 3,520 Total purchase price 10,425 Less cash and cash equivalents acquired (17 ) Total purchase price, net of cash acquired $ 10,408 The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the NorMedix acquisition: Fair Value (Dollars in thousands) Estimated Useful Life (In years) Net current assets $ 113 N/A Property and equipment 60 7.0 Developed technology 6,850 10.0-14.0 Customer relationships 900 4.0 Deferred tax asset 690 N/A Other noncurrent asset 13 N/A Accounts payable (187 ) N/A Deferred tax liabilities (2,483 ) N/A Net assets acquired 5,956 Goodwill 4,452 N/A Total purchase price, net of cash acquired $ 10,408 The NorMedix goodwill is a result of acquiring and retaining the NorMedix existing workforce and expected synergies from integrating their business into the Medical Device segment. The goodwill is not deductible for tax purposes. On a pro forma basis, as if the Creagh Medical and NorMedix acquisitions had occurred as of the beginning of fiscal 2016, the Company’s consolidated revenues would have been

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The accounting guidance on fair value measurements defines fair value, establishes a framework for measuring fair value under GAAP, and expands disclosures about fair value measurements. The guidance is applicable for all financial assets and financial liabilities and for all nonfinancial assets and nonfinancial liabilities recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. Fair Value Hierarchy Accounting guidance on fair value measurements requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1 — Quoted (unadjusted) prices in active markets for identical assets or liabilities. The Company did not have any Level 1 assets as of June 30, 2017 and September 30, 2016. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. The Company’s Level 2 assets as of June 30, 2017 and September 30, 2016 consisted of money market funds, commercial paper instruments and corporate bonds. Level 3 — Unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation. Level 3 liabilities at June 30, 2017 and September 30, 2016 consist of contingent consideration obligations for the achievement of revenue and value-creating milestones related to the acquisitions of Creagh Medical and NorMedix discussed in Note 3. In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. Assets and Liabilities Measured at Fair Value on a Recurring Basis In instances where the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability. The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2017: (Dollars in thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value as of June 30, 2017 Assets Cash equivalents $ — $ 5,953 $ — $ 5,953 Available-for-sale securities — 32,360 — 32,360 Total assets $ — $ 38,313 $ — $ 38,313 Liabilities Contingent consideration $ — $ — $ (13,841 ) $ (13,841 ) Total liabilities $ — $ — $ (13,841 ) $ (13,841 ) The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2016: (Dollars in thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value as of September 30, 2016 Assets Cash equivalents $ — $ 22,160 $ — $ 22,160 Available-for-sale securities — 21,954 — $ 21,954 Total assets $ — $ 44,114 $ — $ 44,114 Liabilities Contingent consideration $ — $ — $ (14,517 ) $ (14,517 ) Total liabilities $ — $ — $ (14,517 ) $ (14,517 ) The following table summarizes the changes in the contingent consideration liabilities measured at fair value using Level 3 inputs for the three and nine months ended June 30, 2017 and 2016: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2017 2016 2017 2016 Beginning balance $ 13,870 $ 13,646 $ 14,517 $ — Additions — — — 12,581 Fair value adjustments (1,192 ) 70 (2,350 ) 70 Settlements — — — — Interest accretion 563 485 1,547 986 Foreign currency translation loss (gain) 600 (251 ) 127 313 Ending balance $ 13,841 $ 13,950 $ 13,841 $ 13,950 There were no transfers of assets or liabilities between amounts measured using Level 1, Level 2, or Level 3 fair value measurements during fiscal 2017 to date or fiscal 2016. Valuation Techniques The valuation techniques used to measure the fair value of assets are as follows: Cash equivalents — These assets are classified as Level 2 and are carried at historical cost which is a reasonable estimate of fair value because of the relatively short time between origination of the instrument and its expected realization. Available-for-sale securities — Fair market values for these assets are based on quoted vendor prices and broker pricing in active markets underlying the securities where all significant inputs are observable. To ensure the accuracy of quoted vendor prices and broker pricing, the Company performs regular reviews of investment returns to industry benchmarks and sample tests of individual securities to validate quoted vendor prices with other available market data. Contingent consideration — The contingent consideration liabilities were determined based on discounted cash flow analyses that included revenue estimates, probability of strategic milestone achievement and a discount rate, which are considered significant unobservable inputs. During the three and nine months ended June 30, 2017, we recorded gains of $1.2 million and $2.4 million, respectively, related to downward adjustments to the estimated fair value of certain revenue and strategic milestones related to the Creagh Medical and NorMedix acquisitions as the probability of the milestones being achieved was reduced. For the Creagh Medical and NorMedix revenue-based milestones, the Company discounted forecasted revenue by 14.0% to 23.5%, respectively, which represents the Company’s weighted average cost of capital for each transaction, adjusted for the short-term nature of the cash flows. The resulting present value of revenue was used as an input into an option pricing approach, which also considered the Company’s risk of non-payment of the revenue-based milestones. Non-revenue milestones were projected to have a 25-95% probability of achievement and related payments were discounted using the Company’s estimated cost of debt, or 2.7% to 3.0%. To the extent that actual results differ from these estimates, the fair value of the contingent consideration liabilities could change significantly. Accretion expense is recorded as an increase to the contingent consideration liabilities due to the passage of time. The contingent consideration liability related to the Creagh Medical acquisition is denominated in Euros and is not hedged. Foreign currency translation and losses are recorded as this obligation is marked to period-end exchange rates.

Investments

Investments	9 Months Ended
	Jun. 30, 2017
Investments Debt And Equity Securities [Abstract]
Investments	5. Investments Investments consisted principally of commercial paper and corporate bond securities and are classified as available-for-sale as of June 30, 2017 and September 30, 2016. Available-for-sale securities are reported at fair value with unrealized gains and losses, net of tax, excluded from the condensed condensed condensed The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows: June 30, 2017 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper and corporate bonds $ 32,382 $ — $ (22 ) $ 32,360 Total $ 32,382 $ — $ (22 ) $ 32,360 September 30, 2016 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper and corporate bonds $ 22,019 $ — $ (65 ) $ 21,954 Total $ 22,019 $ — $ (65 ) $ 21,954 The following table summarizes sales of available-for-sale debt securities: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2017 2016 2017 2016 Proceeds from maturities $ 17,500 $ — $ 44,571 $ — Gross realized gains — — — — Gross realized losses — — — —

Inventories

Inventories	9 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Inventories	6. Inventories Inventories are principally stated at the lower of cost or market using the specific identification method and include direct labor, materials and overhead, with cost of product sales determined on a first-in, first-out basis. Inventories consisted of the following components: June 30, September 30, (Dollars in thousands) 2017 2016 Raw materials $ 1,643 $ 1,766 Work-in process 584 492 Finished products 1,278 1,321 Total $ 3,505 $ 3,579

Other Assets

Other Assets	9 Months Ended
	Jun. 30, 2017
Investments All Other Investments [Abstract]
Other Assets	7. Other Assets Other assets consist of the following: June 30, September 30, (Dollars in thousands) 2017 2016 ViaCyte, Inc. $ 479 $ 479 Other noncurrent assets 398 149 Other assets, net $ 877 $ 628 The Company has invested a total of $5.3 million in ViaCyte, Inc. (“ViaCyte”), a privately-held California-based biotechnology firm that is developing a unique treatment for diabetes using coated islet cells, the cells that produce insulin in the human body. The balance of the investment of $0.5 million, which is net of previously recorded other-than-temporary impairments of $4.8 million, is accounted for under the cost method and represents less than a 1% ownership interest. The Company does not exert significant influence over ViaCyte’s operating or financial activities. The carrying value of each cost method investment is reviewed quarterly for changes in circumstances or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investment.

Intangible Assets

Intangible Assets	9 Months Ended
	Jun. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	8. Intangible Assets Intangible assets consist principally of acquired patents and technology, customer lists and relationships, licenses and trademarks. The Company recorded amortization expense of $0.6 million and $0.8 million for the three months ended June 30, 2017 and 2016, respectively. The Company recorded amortization expense of 1.9 million for the both nine-month periods ended June 30, 2017 and 2016. Intangible assets consisted of the following: June 30, 2017 (Dollars in thousands) Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 17,888 $ (7,349 ) $ 10,539 Core technology 8.0 530 (530 ) — Developed technology 10.8 9,216 (1,247 ) 7,969 Non-compete 5.0 230 (92 ) 138 Patents and other 16.5 2,321 (1,387 ) 934 Subtotal 30,185 (10,605 ) 19,580 Unamortized intangible assets: In-process research and development 1,004 — 1,004 Trademarks and trade names 646 — 646 Total $ 31,835 $ (10,605 ) $ 21,230 September 30, 2016 (Dollars in thousands) Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 17,692 $ (6,123 ) $ 11,569 Core technology 8.0 530 (530 ) — Developed technology 11.8 8,724 (618 ) 8,106 Non-compete 5.0 230 (58 ) 172 Patents and other 16.5 2,321 (1,275 ) 1,046 Subtotal 29,497 (8,604 ) 20,893 Unamortized intangible assets: In-process research and development 987 — 987 Trademarks and trade names 645 — 645 Total $ 31,129 $ (8,604 ) $ 22,525 Based on the intangible assets in service as of June 30, 2017, excluding any possible future amortization associated with acquired in-process research and development (“IPR&D”), which has not met technological feasibility as of June 30, 2017, estimated amortization expense for the remainder of fiscal 2017 and each of the next five fiscal years is as follows: (Dollars in thousands) Remainder of 2017 $ 699 2018 2,606 2019 2,606 2020 2,430 2021 2,291 2022 2,251 Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of future acquisitions, impairments, completion or abandonment of IPR&D intangible assets, changes in amortization periods, or other factors. The Company defines IPR&D as the value of technology acquired for which the related projects have substance and are incomplete. IPR&D acquired in a business acquisition is recognized at fair value and requires the IPR&D to be capitalized as an indefinite-lived intangible asset until completion of the IPR&D project or abandonment. Upon completion of the development project (generally when regulatory approval to market the product is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. If the IPR&D projects are abandoned, the related IPR&D assets would be written off.

Goodwill

Goodwill	9 Months Ended
	Jun. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	9. Goodwill Goodwill represents the excess of the cost of an acquired entity over the fair value assigned to the assets purchased and liabilities assumed in connection with a business acquisition. Goodwill is not amortized but is subject, at a minimum, to annual tests for impairment in accordance with accounting guidance for goodwill. The carrying amount of goodwill is evaluated annually, and between annual evaluations if events occur or circumstances change indicating that the carrying amount of goodwill may be impaired. Goodwill as of June 30, 2017 and September 30, 2016 totaled $26.8 million and $26.6 million, respectively. Goodwill in the Medical Device reporting unit represents the gross value from the acquisitions of Creagh Medical and NorMedix in fiscal 2016. Goodwill in the In Vitro Diagnostics reporting unit represents the gross value from the acquisition of BioFX Laboratories, Inc. (“BioFX”) in fiscal 2007. Goodwill was not impaired in either reporting unit based on the outcome of the fiscal 2016 annual impairment test, and there have been no events or circumstances that have occurred in the first nine months of fiscal 2017 to indicate that goodwill has been impaired. The change in the carrying amount of goodwill by segment for the nine months ended June 30, 2017 was as follows: (Dollars in thousands) In Vitro Diagnostics Medical Device Total Balance as of September 30, 2016 $ 8,010 $ 18,545 $ 26,555 Currency translation adjustment — 236 236 Balance as of June 30, 2017 $ 8,010 $ 18,781 $ 26,791

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Jun. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	10. Stock-based Compensation The Company has stock-based compensation plans under which it grants stock options, restricted stock awards, performance share awards, restricted stock units and deferred stock units. Accounting guidance requires all share-based payments to be recognized as an operating expense, based on their fair values, over the requisite service period. The Company’s stock-based compensation expenses were allocated to the following expense categories: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2017 2016 2017 2016 Product costs $ 19 $ 4 $ 69 $ 12 Research and development 139 101 387 220 Selling, general and administrative 790 725 2,164 2,497 Total $ 948 $ 830 $ 2,620 $ 2,729 As of June 30, 2017, approximately $5.3 million of total unrecognized compensation costs related to non-vested awards is expected to be recognized over a weighted average period of approximately 2.2 years. The unrecognized compensation costs above include $2.0 million, remaining to be expensed over the life of the awards, based on payout levels associated with performance share awards that are currently anticipated to be fully expensed because the performance conditions are expected to exceed minimum threshold levels. Stock Option Awards The Company uses the Black-Scholes option pricing model to determine the weighted average grant date fair value of stock options granted. The weighted average per share fair values of stock options granted during the three months ended June 30, 2017 and 2016 were $7.22 and $6.49, respectively, and $7.57 and $6.85 during the nine months ended June 30, 2017 and 2016, respectively. The assumptions used as inputs in the model were as follows: Three Months Ended Nine Months Ended June 30, June 30, 2017 2016 2017 2016 Risk-free interest rates 1.8 % 1.3 % 1.7 % 1.9 % Expected life (years) 4.7 4.7 4.6 4.6 Expected volatility 33.3 % 35.2 % 34.3 % 36.8 % Dividend yield 0.0 % 0.0 % 0.0 % 0.0 % The risk-free interest rate assumption was based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award. The expected life of options granted was determined based on the Company’s experience. Expected volatility was based on the Company’s stock price movement over a period approximating the expected term. Based on management’s judgment, dividend yields were expected to be 0.0% for the expected life of the options. The Company also estimated forfeitures of options granted, which were based on historical experience. Non-qualified stock options are granted at fair market value on the date of grant. Non-qualified stock options expire in seven to ten years or upon termination of employment or service as a Board member. With respect to members of our Board, non-qualified stock options generally become exercisable on a pro-rata basis within the one-year period following the date of grant. With respect to our employees, non-qualified stock options generally become exercisable with respect to 25% of the shares on each of the first four anniversaries following the grant date. The stock-based compensation table above includes stock option expenses recognized related to these awards, which totaled $0.3 million for both the three-month periods ended June 30, 2017 and 2016, and $0.9 million for both the nine-month periods ended June 30, 2017 and 2016. The total pre-tax intrinsic value of options exercised during the three and nine months ended June 30, 2017 was less than $0.1 million in each period. The total pre-tax intrinsic value of options exercised during the three and nine months ended June 30, 2016 was $0.4 million and $1.7 million, respectively. The intrinsic value represents the difference between the average exercise price and the fair market value of the Company’s common stock on the last day of the respective fiscal period end. Restricted Stock Awards The Company has entered into restricted stock agreements with certain key employees, covering the issuance of common stock (“Restricted Stock”). Under accounting guidance, these shares are considered to be non-vested shares. The Restricted Stock is released to the key employees if they are employed by the Company at the end of the vesting period. Compensation expense has been recognized for the estimated fair value of the common shares and is being charged to income over the vesting term. The stock-based compensation expense table includes Restricted Stock expenses recognized related to these awards, which totaled $0.1 million for both the three-month periods ended June 30, 2017 and 2016, and $0.4 million and $0.2 million for the nine-month periods ended June 30, 2017 and 2016, respectively. Performance Share Awards The Company has entered into performance share agreements with certain key employees and executives, covering the issuance of common stock (“Performance Shares”). Performance Shares vest upon the achievement of all or a portion of certain performance objectives (which may include financial or project objectives), which must be achieved during the performance period. The Organization and Compensation Committee of the Board of Directors (the “Committee”) approves the performance objectives used for our executive compensation programs, which objectives were cumulative revenue and cumulative earnings before interest, income taxes, depreciation and amortization (“EBITDA”) for the three-year performance periods for awards granted in fiscal 2015 (2015 – 2017), fiscal 2016 (2016 – 2018) and fiscal 2017 (2017 – 2019). The fiscal 2017 awards also include performance objectives related to achievement of the Company’s strategic initiatives. Assuming that the minimum performance level is attained, the number of shares that may actually vest will vary based on performance from 20% (minimum) to 200% (maximum) of the target number of shares. Shares will be issued to participants as soon as practicable following the end of each performance period, subject to Committee approval and verification of results. Awards granted in fiscal 2014 were finalized in the nine months ended June 30, 2017 and resulted in the issuance of 38,505 shares (maximum was 78,606 shares) based on the performance objectives relative to actual results achieved during the performance period. The per share compensation cost for each award is fixed on the grant date. Compensation expense is recognized in each period based on management’s best estimate of the achievement level of actual and forecasted results, as appropriate, compared with the specified performance objectives and the related impact on the number of Performance Shares expected to vest. The stock-based compensation expense table includes the Performance Shares expenses recognized related to these awards, which totaled $0.4 million and $0.3 million for the three-month periods ended June 30, 2017 and 2016, respectively, and $1.0 million and $1.3 million for the nine-month periods ended June 30, 2017 and 2016, respectively. The fair values of the Performance Shares, at target, were $1.2 million, $1.3 million and $0.9 million in each fiscal year for awards granted in fiscal 2017, 2016 and 2015, respectively. The aggregate number of shares that could be awarded to our executives if the minimum, target and maximum performance goals are met, based on the fair value at the date of grant is as follows: Performance Period Minimum Shares Target Shares Maximum Shares Fiscal 2015 – 2017 8,440 42,199 84,398 Fiscal 2016 – 2018 13,268 66,338 132,676 Fiscal 2017 – 2019 10,437 52,185 104,370 Employee Stock Purchase Plan Under the Employee Stock Purchase Plan (“Stock Purchase Plan”), the Company is authorized to issue up to 600,000 shares of common stock. All full-time and part-time U.S. employees can choose to have up to 10% of their annual compensation withheld, with a limit of $25,000, to purchase the Company’s common stock at purchase prices defined within the provisions of the Stock Purchase Plan. As of June 30, 2017 and September 30, 2016, there was less than $0.1 million of employee contributions included in accrued liabilities in the condensed consolidated balance sheets. Stock compensation expense recognized related to the Stock Purchase Plan for the three and nine-month periods ended June 30, 2017 and 2016 totaled less than $0.1 million in each respective period. The stock-based compensation table includes the Stock Purchase Plan expenses. Restricted Stock and Deferred Stock Units During the nine months ended June 30, 2017 and 2016, the Company awarded 16,004 and 18,877 restricted stock units (“RSUs”), respectively, under the 2009 Equity Incentive Plan to non-employee directors and certain key employees in foreign jurisdictions. Forfeiture of 446 RSUs occurred during the nine months ended June 30, 2017. As of June 30, 2017 and September 30, 2016, 44,440 and 32,101 RSUs were outstanding, respectively, with an estimated fair market value of $1.3 million and $0.9 million, respectively. RSU awards are not considered issued or outstanding common stock of the Company until they vest. The estimated fair value of the RSUs was calculated based on the closing market price of Surmodics’ common stock on the date of grant. Compensation expense has been recognized for the estimated fair value of the common shares and is being charged to income over the vesting term. The stock-based compensation table includes RSU expenses recognized related to these awards, which totaled less than $0.1 million for both the three-month periods ended June 30, 2017 and 2016, and $0.2 million and $0.1 million for the respective nine-month periods ended June 30, 2017 and 2016. Directors can also elect to receive their annual fees for services to the Board in deferred stock units (“DSUs”). Certain directors elected this option beginning on January 1, 2013 with deferral elections made annually. During the nine months ended June 30, 2017 and 2016, 2,953 and 6,646 units, respectively, were issued with a total fair value of less than $0.1 million in each period. As of June 30, 2017 and September 30, 2016, outstanding DSUs totaled 24,030 and 21,077, respectively, with an estimated fair value of $0.7 million and $0.6 million, respectively. These DSUs are fully vested. Stock-based compensation expense related to DSU awards totaled less than $0.1 million for both the three-month periods ended June 30, 2017 and 2016, and $0.1 million for both the nine-month periods ended June 30, 2017 and 2016.

Revolving Credit Facility

Revolving Credit Facility	9 Months Ended
	Jun. 30, 2017
Text Block [Abstract]
Revolving Credit Facility	11. Revolving Credit Facility On November 2, 2016, the Company amended and restated its revolving credit facility. The new agreement increased the available principal to $30.0 million and extended the maturity to November 2019. In addition, the agreement includes a $5.0 million multi-currency overdraft facility in Ireland. Borrowings under the credit facility, if any, will bear interest at a benchmark rate plus a margin ranging from 1.00% to 1.75% based on the Company’s leverage ratio, as defined in the loan agreement. A facility fee is payable quarterly on unused commitments at a rate of 0.15% per annum. The Company has the option to increase the credit facility in increments of $5.0 million up to an additional $20.0 million, subject to approval of the lender. The Company’s obligations under the credit facility are secured by substantially all of its assets, other than intellectual property and real estate, as well as the majority of its equity interest in its subsidiaries. In connection with the credit facility, the Company is required to comply with certain financial and non-financial covenants. As of June 30, 2017, the Company has no debt outstanding and was in compliance with all financial covenants.

Net Income Per Share Data

Net Income Per Share Data	9 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Net Income Per Share Data	12. Net Income Per Share Data Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and common equivalent shares outstanding during the period. The Company’s potentially dilutive common shares are those that result from dilutive common stock options, non-vested stock relating to restricted stock awards, restricted stock units, deferred stock units and performance shares. The following table sets forth the denominator for the computation of basic and diluted net income per share (in thousands): Three Months Ended Nine Months Ended June 30, June 30, 2017 2016 2017 2016 Net income available to common shareholders $ 720 $ 3,934 $ 3,526 $ 7,408 Basic weighted average shares outstanding 13,155 12,995 13,190 12,969 Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares 230 289 214 234 Diluted weighted average shares outstanding 13,385 13,284 13,404 13,203 The calculation of weighted average diluted shares outstanding excludes outstanding stock options associated with the right to purchase 0.1 million and 0.3 million shares of common stock for the three months ended June 30, 2017 and 2016, respectively, and $0.1 million and 0.2 million for the nine months ended June 30, 2017 and 2016, respectively, as their inclusion would have had an antidilutive effect on diluted net income per share. The Company’s Board of Directors has authorized the repurchase of up to $30.0 million of the Company’s outstanding common stock. This authorization does not have an expiration date. During the third quarter of fiscal 2017, the Company repurchased 169,868 shares of common stock at an average price of $23.78 per share for a total of $4.0 million. As of June 30, 2017, the Company has $26.0 million available for future repurchases under the current authorization.

Income Taxes

Income Taxes	9 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes For interim income tax reporting, the Company estimates its annual effective tax rate and applies it to year-to-date pretax income, excluding unusual or infrequently occurring discrete items. Tax jurisdictions with losses for which tax benefits cannot be realized are excluded. The Company recorded income tax provisions of $0.5 million and $2.9 million for the three months ended June 30, 2017 and 2016, respectively, representing effective tax rates, defined as income tax expense divided by income before taxes, of 42.5% and 42.8%, respectively. The Company recorded income tax provisions of $3.3 million and $5.4 million for the nine months ended June 30, 2017 and 2016, respectively, representing effective tax rates of 48.5% and 42.3%, respectively. The Company’s effective tax reflects the impact of state income taxes, permanent tax items and discrete tax benefits. The effective income tax rate for the three and nine-month periods ended June 30, 2017 and 2016 The total amount of unrecognized tax benefits, excluding interest and penalties that, if recognized, would affect the effective tax rate is $1.2 million as of June 30, 2017 and September 30, 2016. Currently, the Company does not expect the liability for unrecognized tax benefits to change significantly in the next 12 months with the above balances classified on the condensed consolidated balance sheets in other long-term liabilities. Interest and penalties related to unrecognized tax benefits are recorded in income tax provision. The Company files income tax returns, including returns for its subsidiaries, in the U.S. federal jurisdiction and in various state jurisdictions as well as several non-U.S. jurisdictions. Uncertain tax positions are related to tax years that remain subject to examination. U.S. income tax returns for years prior to fiscal 2014 are no longer subject to examination by federal tax authorities. For tax returns for state and local jurisdictions, the Company is no longer subject to examination for tax years generally before fiscal 2007. For tax returns for non-U.S. jurisdictions, the Company is no longer subject to income tax examination for years prior to 2012. Additionally, the Company has been indemnified of liability for any taxes relating to Creagh Medical and NorMedix for periods prior to the respective acquisition dates, pursuant to the terms of the related share purchase agreements. As of June 30, 2017 and September 30, 2016, there were no undistributed earnings in foreign subsidiaries.

Segment and Geographical Inform

Segment and Geographical Information	9 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Segment and Geographical Information	14. Segment and Geographical Information The Company’s management evaluates performance and allocates resources based on reported results for two reportable segments, as follows: (1) the Medical Device unit, which is comprised of manufacturing balloons and catheters used for a variety of interventional cardiology, peripheral and other applications, surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device, with end markets that include coronary, peripheral, and neurovascular, and urology, among others, and (2) the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic immunoassay as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings. During fiscal 2016, the Company acquired Creagh Medical and NorMedix, which are included in the Medical Device segment subsequent to the respective acquisition dates, as further discussed in Note 3. The tables below present segment revenue, operating income and depreciation and amortization, as follows: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2017 2016 2017 2016 Revenue: Medical Device $ 12,778 $ 15,654 $ 39,260 $ 39,500 In Vitro Diagnostics 5,012 4,318 13,794 13,712 Total revenue $ 17,790 $ 19,972 $ 53,054 $ 53,212 Operating income: Medical Device $ 1,403 $ 6,673 $ 6,627 $ 12,825 In Vitro Diagnostics 2,230 1,673 5,922 5,298 Total segment operating income 3,633 8,346 12,549 18,123 Corporate (1,890 ) (1,749 ) (5,861 ) (5,347 ) Total operating income $ 1,743 $ 6,597 $ 6,688 $ 12,776 Depreciation and amortization: Medical Device $ 1,132 $ 982 $ 3,180 $ 2,440 In Vitro Diagnostics 103 222 309 647 Corporate 170 202 517 616 Total depreciation and amortization $ 1,405 $ 1,406 $ 4,006 $ 3,703 The Corporate category includes expenses that are not fully allocated to Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses, such as litigation, which are not specific to a segment and thus not allocated to the operating segments. Asset information by operating segment is not presented because the Company does not provide its chief operating decision maker assets by operating segment, as the data is not readily available or significant to the decision-making process.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies Litigation. From time to time, the Company may become involved in various legal actions involving its operations, products and technologies, including intellectual property and employment disputes. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages as well as other relief, including injunctions barring the sale of products that are the subject of the lawsuit, which if granted, could require significant expenditures or result in lost revenue. The Company records a liability in the condensed consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. On February 22, 2017, the Company was sued by Merit Medical Systems, Inc. (“Merit”) in the U.S. District Court for the District of Utah. NorMedix was added as a defendant on April 3, 2017. The lawsuit alleges breach of contract and seeks declaratory relief in connection with a services agreement entered into between Merit and NorMedix on March 3, 2015. In the lawsuit, Merit claims that certain technology and intellectual property related to thin-walled catheter technologies were developed by NorMedix under the services agreement and, pursuant to the terms of that agreement, should be owned by Merit. Pretrial proceedings are underway. The Company has not recorded an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter. Under the stock purchase agreement, pursuant to which the Company acquired NorMedix, the Company may have certain rights of indemnification against losses (including, without limitation, damages, expenses and costs) incurred as a result of the claims asserted in the litigation. The Company believes that the claims in the lawsuit are without merit and plans to vigorously defend and prosecute this matter. InnoCore Technologies BV . In March 2006, the Company entered into a license agreement whereby Surmodics obtained an exclusive license to a drug delivery coating for licensed products within the vascular field which included peripheral, coronary and neurovascular biodurable stent products. The license requires an annual minimum payment of 200,000 euros (equivalent to $228,000 using a euro to US dollar exchange rate of 1.1409 to the Euro as of June 30, 2017) until the last patent expires which is currently estimated to be September 2027. The total minimum future payments associated with this license are approximately $2.3 million. The license is currently utilized by one of the Company’s drug delivery customers.

New Accounting Pronouncements (

New Accounting Pronouncements (Policies)	9 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
New Accounting Pronouncements	Accounting Standards to be Implemented In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2014-09, Revenue from Contracts with Customers (ASC Topic 606) In February 2016, the FASB issued Accounting Standards Update ASU 2016-02, Leases (ASC Topic 842) In June 2016, the FASB issued ASU No 2016-13, Financial Instruments – Credit Losses (ASC Topic 326), Measurement of Credit Losses on Financial Statements In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In January 2017, the FASB issued ASU No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment Accounting Standards Implemented In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (ASC Topic 718): Improvements to Employee Share-Based Payment Accounting As a result of the adoption, the Company records excess tax benefits and certain tax deficiencies as income tax expense or benefit in the condensed consolidated statements of income, whereas such excess tax benefits or tax deficiencies were previously recorded in additional paid-in capital. As this guidance was applied retroactively to the beginning of the fiscal year ended September 30, 2016, previously reported quarterly income tax and net income for interim periods therein were adjusted for the effects of the adoption. This resulted in adjustments to increase the income tax provision and decrease net income by less than $0.1 million for the three months ended June 30, 2016 and to reduce the income tax provision and increase net income by less than $0.1 million for the nine months ended June 30, 2016. The adoption of this ASU also resulted in a (reduction) increase in net income per basic and diluted share of less than ($0.01) per share and $0.01 per share, respectively, for the three and nine-month periods ended June 30, 2016 The newly adopted guidance also requires presentation of excess tax benefits as an operating activity on the statement of cash flows rather than as a financing activity Prior to the adoption of ASU No. 2016-09, cash flows resulting from the tax benefits generated by tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) were classified as financing cash flows. During the nine months ended June 30, 2016, the Company realized tax benefits from stock options resulting in approximately $0.1 million of gross excess tax benefits, which are included as a component of cash flows from operating activities in the accompanying condensed consolidated statements of cash flows. This amount was previously reported as a component of cash flows from financing activities, but has been reclassified to conform to current accounting guidance. No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Jun. 30, 2017
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Summary of Purchase Price	The purchase price of Creagh Medical consisted of the following: (Dollars in thousands) Cash paid $ 18,449 Debt assumed 761 Contingent consideration 9,064 Total purchase price 28,274 Less cash and cash equivalents acquired (251 ) Total purchase price, net of cash acquired $ 28,023
Schedule of Purchase Price to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed	The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the Creagh Medical acquisition: Fair Value (Dollars in thousands) Estimated Useful Life (In years) Current assets $ 896 N/A Property and equipment 634 1.0-10.0 Trade name 75 N/A Developed technology 1,787 7.0 In-process research and development 942 N/A Customer relationships 11,119 7.0-10.0 Other noncurrent assets 81 N/A Current liabilities (942 ) N/A Deferred tax liabilities (9 ) N/A Net assets acquired 14,583 Goodwill 13,440 N/A Total purchase price, net of cash acquired $ 28,023
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Summary of Purchase Price	The purchase price of NorMedix consisted of the following: (Dollars in thousands) Cash paid $ 6,905 Contingent consideration 3,520 Total purchase price 10,425 Less cash and cash equivalents acquired (17 ) Total purchase price, net of cash acquired $ 10,408
Schedule of Purchase Price to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed	The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the NorMedix acquisition: Fair Value (Dollars in thousands) Estimated Useful Life (In years) Net current assets $ 113 N/A Property and equipment 60 7.0 Developed technology 6,850 10.0-14.0 Customer relationships 900 4.0 Deferred tax asset 690 N/A Other noncurrent asset 13 N/A Accounts payable (187 ) N/A Deferred tax liabilities (2,483 ) N/A Net assets acquired 5,956 Goodwill 4,452 N/A Total purchase price, net of cash acquired $ 10,408

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2017: (Dollars in thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value as of June 30, 2017 Assets Cash equivalents $ — $ 5,953 $ — $ 5,953 Available-for-sale securities — 32,360 — 32,360 Total assets $ — $ 38,313 $ — $ 38,313 Liabilities Contingent consideration $ — $ — $ (13,841 ) $ (13,841 ) Total liabilities $ — $ — $ (13,841 ) $ (13,841 ) The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2016: (Dollars in thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value as of September 30, 2016 Assets Cash equivalents $ — $ 22,160 $ — $ 22,160 Available-for-sale securities — 21,954 — $ 21,954 Total assets $ — $ 44,114 $ — $ 44,114 Liabilities Contingent consideration $ — $ — $ (14,517 ) $ (14,517 ) Total liabilities $ — $ — $ (14,517 ) $ (14,517 )
Schedule of Contingent Consideration Liabilities Measured at Fair Value	The following table summarizes the changes in the contingent consideration liabilities measured at fair value using Level 3 inputs for the three and nine months ended June 30, 2017 and 2016: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2017 2016 2017 2016 Beginning balance $ 13,870 $ 13,646 $ 14,517 $ — Additions — — — 12,581 Fair value adjustments (1,192 ) 70 (2,350 ) 70 Settlements — — — — Interest accretion 563 485 1,547 986 Foreign currency translation loss (gain) 600 (251 ) 127 313 Ending balance $ 13,841 $ 13,950 $ 13,841 $ 13,950

Investments (Tables)

Investments (Tables)	9 Months Ended
	Jun. 30, 2017
Investments Debt And Equity Securities [Abstract]
Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities	The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows: June 30, 2017 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper and corporate bonds $ 32,382 $ — $ (22 ) $ 32,360 Total $ 32,382 $ — $ (22 ) $ 32,360 September 30, 2016 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper and corporate bonds $ 22,019 $ — $ (65 ) $ 21,954 Total $ 22,019 $ — $ (65 ) $ 21,954
Sales of Available-for-Sale Debt Securities	The following table summarizes sales of available-for-sale debt securities: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2017 2016 2017 2016 Proceeds from maturities $ 17,500 $ — $ 44,571 $ — Gross realized gains — — — — Gross realized losses — — — —

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Components of Inventories	Inventories consisted of the following components: June 30, September 30, (Dollars in thousands) 2017 2016 Raw materials $ 1,643 $ 1,766 Work-in process 584 492 Finished products 1,278 1,321 Total $ 3,505 $ 3,579

Other Assets (Tables)

Other Assets (Tables)	9 Months Ended
	Jun. 30, 2017
Investments All Other Investments [Abstract]
Summary of Other Assets	Other assets consist of the following: June 30, September 30, (Dollars in thousands) 2017 2016 ViaCyte, Inc. $ 479 $ 479 Other noncurrent assets 398 149 Other assets, net $ 877 $ 628

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Jun. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following: June 30, 2017 (Dollars in thousands) Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 17,888 $ (7,349 ) $ 10,539 Core technology 8.0 530 (530 ) — Developed technology 10.8 9,216 (1,247 ) 7,969 Non-compete 5.0 230 (92 ) 138 Patents and other 16.5 2,321 (1,387 ) 934 Subtotal 30,185 (10,605 ) 19,580 Unamortized intangible assets: In-process research and development 1,004 — 1,004 Trademarks and trade names 646 — 646 Total $ 31,835 $ (10,605 ) $ 21,230 September 30, 2016 (Dollars in thousands) Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 17,692 $ (6,123 ) $ 11,569 Core technology 8.0 530 (530 ) — Developed technology 11.8 8,724 (618 ) 8,106 Non-compete 5.0 230 (58 ) 172 Patents and other 16.5 2,321 (1,275 ) 1,046 Subtotal 29,497 (8,604 ) 20,893 Unamortized intangible assets: In-process research and development 987 — 987 Trademarks and trade names 645 — 645 Total $ 31,129 $ (8,604 ) $ 22,525
Estimated Amortization Expense	Based on the intangible assets in service as of June 30, 2017, excluding any possible future amortization associated with acquired in-process research and development (“IPR&D”), which has not met technological feasibility as of June 30, 2017, estimated amortization expense for the remainder of fiscal 2017 and each of the next five fiscal years is as follows: (Dollars in thousands) Remainder of 2017 $ 699 2018 2,606 2019 2,606 2020 2,430 2021 2,291 2022 2,251

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Jun. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule Of Carrying Amount Of Goodwill By Segment	The change in the carrying amount of goodwill by segment for the nine months ended June 30, 2017 was as follows: (Dollars in thousands) In Vitro Diagnostics Medical Device Total Balance as of September 30, 2016 $ 8,010 $ 18,545 $ 26,555 Currency translation adjustment — 236 236 Balance as of June 30, 2017 $ 8,010 $ 18,781 $ 26,791

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Jun. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation Expenses	The Company’s stock-based compensation expenses were allocated to the following expense categories: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2017 2016 2017 2016 Product costs $ 19 $ 4 $ 69 $ 12 Research and development 139 101 387 220 Selling, general and administrative 790 725 2,164 2,497 Total $ 948 $ 830 $ 2,620 $ 2,729
Assumptions Used in Stock Option Plans	The assumptions used as inputs in the model were as follows: Three Months Ended Nine Months Ended June 30, June 30, 2017 2016 2017 2016 Risk-free interest rates 1.8 % 1.3 % 1.7 % 1.9 % Expected life (years) 4.7 4.7 4.6 4.6 Expected volatility 33.3 % 35.2 % 34.3 % 36.8 % Dividend yield 0.0 % 0.0 % 0.0 % 0.0 %
Schedule of Fair Value at the Date of Grant	The aggregate number of shares that could be awarded to our executives if the minimum, target and maximum performance goals are met, based on the fair value at the date of grant is as follows: Performance Period Minimum Shares Target Shares Maximum Shares Fiscal 2015 – 2017 8,440 42,199 84,398 Fiscal 2016 – 2018 13,268 66,338 132,676 Fiscal 2017 – 2019 10,437 52,185 104,370

Net Income Per Share Data (Tabl

Net Income Per Share Data (Tables)	9 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Denominator for Computation of Basic and Diluted Net Income Per Share	The following table sets forth the denominator for the computation of basic and diluted net income per share (in thousands): Three Months Ended Nine Months Ended June 30, June 30, 2017 2016 2017 2016 Net income available to common shareholders $ 720 $ 3,934 $ 3,526 $ 7,408 Basic weighted average shares outstanding 13,155 12,995 13,190 12,969 Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares 230 289 214 234 Diluted weighted average shares outstanding 13,385 13,284 13,404 13,203

Segment and Geographical Info32

Segment and Geographical Information (Tables)	9 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Segment Revenue, Operating Income and Depreciation and Amortization	The tables below present segment revenue, operating income and depreciation and amortization, as follows: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2017 2016 2017 2016 Revenue: Medical Device $ 12,778 $ 15,654 $ 39,260 $ 39,500 In Vitro Diagnostics 5,012 4,318 13,794 13,712 Total revenue $ 17,790 $ 19,972 $ 53,054 $ 53,212 Operating income: Medical Device $ 1,403 $ 6,673 $ 6,627 $ 12,825 In Vitro Diagnostics 2,230 1,673 5,922 5,298 Total segment operating income 3,633 8,346 12,549 18,123 Corporate (1,890 ) (1,749 ) (5,861 ) (5,347 ) Total operating income $ 1,743 $ 6,597 $ 6,688 $ 12,776 Depreciation and amortization: Medical Device $ 1,132 $ 982 $ 3,180 $ 2,440 In Vitro Diagnostics 103 222 309 647 Corporate 170 202 517 616 Total depreciation and amortization $ 1,405 $ 1,406 $ 4,006 $ 3,703

New Accounting Pronouncements -

New Accounting Pronouncements - Additional Information (Detail) - ASU 2016-09 [Member] - USD ($)	3 Months Ended	9 Months Ended
	Jun. 30, 2016	Jun. 30, 2016
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Adjustments to increase (reduce) income tax provision		$ (100,000)
Adjustments to increase (decrease) net income		$ 100,000
(Decrease) increase in net income per basic and diluted share		$ 0.01
Excess tax benefit from stock-based compensation plans		$ 100,000
Maximum [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Adjustments to increase (reduce) income tax provision	$ 100,000
Adjustments to increase (decrease) net income	$ (100,000)
(Decrease) increase in net income per basic and diluted share	$ (0.01)

Business Combinations - Additio

Business Combinations - Additional Information (Detail) $ / shares in Units, $ in Thousands, € in Millions	Jan. 08, 2016USD ($)	Nov. 20, 2015USD ($)	Nov. 20, 2015EUR (€)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)$ / shares	Sep. 30, 2016USD ($)	Nov. 20, 2015EUR (€)
Business Acquisition [Line Items]
Acquisition transaction, integration and other costs					$ 61				$ 3,192
Business acquisition, revenue recognized				$ 17,790	19,972			$ 53,054	53,212
Business acquisition, loss recognized				$ 720	3,934			3,526	7,408
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Outstanding common shares and voting shares percentage		100.00%									100.00%
Payments to acquire business								28,274
Upfront payments		$ 19,300	€ 18					18,449
Contingent milestone payments		12,800									€ 12
Acquisition transaction, integration and other costs					100				2,700
Business acquisition, revenue recognized							$ 2,200
Business acquisition, loss recognized							$ (2,200)
Creagh Medical Ltd [Member] | Maximum [Member]
Business Acquisition [Line Items]
Payments to acquire business		$ 32,000	€ 30
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Outstanding common shares and voting shares percentage	100.00%
Payments to acquire business								10,425
Upfront payments	$ 7,000							$ 6,905
Contingent milestone payments	7,000
Acquisition transaction, integration and other costs					$ 0				300
Business acquisition, revenue recognized						$ 600
Business acquisition, loss recognized						$ (200)
NorMedix, Inc. [Member] | Maximum [Member]
Business Acquisition [Line Items]
Payments to acquire business	$ 14,000
Creagh Medical and NorMedix [Member]
Business Acquisition [Line Items]
Consolidated pro forma revenue									54,300
Consolidated pro forma net income									$ 6,900
Basic earnings per share | $ / shares									$ 0.53
Diluted earnings per share | $ / shares									$ 0.52
Creagh Medical and NorMedix [Member] | Unaudited Pro Forma [Member]
Business Acquisition [Line Items]
Amortization expense on intangible assets										$ 400
Contingent consideration accretion expense										300
Non-recurring professional fees										3,000
Tax effect impact										$ 100

Business Combinations - Summary

Business Combinations - Summary of Purchase Price (Detail) $ in Thousands, € in Millions	Jan. 08, 2016USD ($)	Nov. 20, 2015USD ($)	Nov. 20, 2015EUR (€)	Jun. 30, 2017USD ($)
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Cash Paid		$ 19,300	€ 18	$ 18,449
Debt assumed				761
Contingent consideration				9,064
Total purchase price				28,274
Less cash and cash equivalents acquired				(251)
Total purchase price, net of cash acquired				28,023
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Cash Paid	$ 7,000			6,905
Contingent consideration				3,520
Total purchase price				10,425
Less cash and cash equivalents acquired				(17)
Total purchase price, net of cash acquired				$ 10,408

Business Combinations - Summa36

Business Combinations - Summary of Purchase Price Allocation to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Jun. 30, 2017	Sep. 30, 2016
Business Acquisition [Line Items]
Goodwill	$ 26,791	$ 26,555
Developed Technology [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years 9 months 18 days	11 years 9 months 18 days
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Current assets	$ 896
Property and equipment	634
Other noncurrent assets	81
Current liabilities	(942)
Deferred tax liabilities	(9)
Net assets acquired	14,583
Goodwill	13,440
Total purchase price, net of cash acquired	$ 28,023
Creagh Medical Ltd [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	1 year
Creagh Medical Ltd [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years
Creagh Medical Ltd [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Intangible assets	$ 1,787
Estimated Useful Life (In years)	7 years
Creagh Medical Ltd [Member] | In-Process Research and Development [Member]
Business Acquisition [Line Items]
Intangible assets	$ 942
Creagh Medical Ltd [Member] | Customer Relationship [Member]
Business Acquisition [Line Items]
Intangible assets	$ 11,119
Creagh Medical Ltd [Member] | Customer Relationship [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	7 years
Creagh Medical Ltd [Member] | Customer Relationship [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years
Creagh Medical Ltd [Member] | Trade Name [Member]
Business Acquisition [Line Items]
Intangible assets	$ 75
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Current assets	113
Property and equipment	60
Deferred tax asset	690
Other noncurrent assets	13
Accounts payable	(187)
Deferred tax liabilities	(2,483)
Net assets acquired	5,956
Goodwill	4,452
Total purchase price, net of cash acquired	$ 10,408
Estimated Useful Life (In years)	7 years
NorMedix, Inc. [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Intangible assets	$ 6,850
NorMedix, Inc. [Member] | Developed Technology [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years
NorMedix, Inc. [Member] | Developed Technology [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	14 years
NorMedix, Inc. [Member] | Customer Relationship [Member]
Business Acquisition [Line Items]
Intangible assets	$ 900
Estimated Useful Life (In years)	4 years

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Assets and Liabilities Measured at Fair Value on a Recurring Basis [Member] - USD ($) $ in Thousands	Jun. 30, 2017	Sep. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	$ 38,313	$ 44,114
Liabilities measured at fair value	(13,841)	(14,517)
Available-for-sale securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	32,360	21,954
Cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	5,953	22,160
Contingent consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	(13,841)	(14,517)
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	38,313	44,114
Significant Other Observable Inputs (Level 2) [Member] | Available-for-sale securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	32,360	21,954
Significant Other Observable Inputs (Level 2) [Member] | Cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	5,953	22,160
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	(13,841)	(14,517)
Significant Unobservable Inputs (Level 3) [Member] | Contingent consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	$ (13,841)	$ (14,517)

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Contingent Consideration Liabilities Measured at Fair Value (Detail) - Contingent Consideration [Member] - Significant Unobservable Inputs (Level 3) [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 13,870	$ 13,646	$ 14,517
Additions				$ 12,581
Fair value adjustments	(1,192)	70	(2,350)	70
Interest accretion	563	485	1,547	986
Foreign currency translation loss (gain)	600	(251)	127	313
Ending balance	$ 13,841	$ 13,950	$ 13,841	$ 13,950

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Sep. 30, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Transfers in or out Level 3, Assets		$ 0	$ 0
Transfers in or out Level 3, Liabilities		0	0
Transfers out of Level 1 to Level 2, Assets	$ 0	0	0
Transfers into Level 1 out of Level 2, Assets	0	0	0
Transfers out of Level 1 to Level 2, Liabilities	0	0	0
Transfers into Level 1 out of Level 2, Liabilities	0	0	$ 0
Creagh Medical and NorMedix [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value of revenue and strategic milestones, gains related to downward adjustments	$ 1,200,000	$ 2,400,000
Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Percentage of Probability Achievement of Contingent Consideration payment.		25.00%
Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Percentage of Probability Achievement of Contingent Consideration payment.		95.00%
Contingent Consideration [Member] | Minimum [Member] | Non Revenue Based Milestones [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate		2.70%
Contingent Consideration [Member] | Minimum [Member] | Revenue Based Milestones [Member] | Creagh Medical and NorMedix [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate		14.00%
Contingent Consideration [Member] | Maximum [Member] | Non Revenue Based Milestones [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate		3.00%
Contingent Consideration [Member] | Maximum [Member] | Revenue Based Milestones [Member] | Creagh Medical and NorMedix [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate		23.50%

Investments - Amortized Cost, U

Investments - Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Sep. 30, 2016
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 32,382	$ 22,019
Unrealized Losses	(22)	(65)
Fair Value	32,360	21,954
Commercial paper and corporate bonds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	32,382	22,019
Unrealized Losses	(22)	(65)
Fair Value	$ 32,360	$ 21,954

Investments - Sales of Availabl

Investments - Sales of Available-for-Sale Securities (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Jun. 30, 2017	Jun. 30, 2017
Investments Debt And Equity Securities [Abstract]
Proceeds from maturities	$ 17,500	$ 44,571

Inventories - Components of Inv

Inventories - Components of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Sep. 30, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 1,643	$ 1,766
Work-in process	584	492
Finished products	1,278	1,321
Total	$ 3,505	$ 3,579

Other Assets - Summary of Other

Other Assets - Summary of Other Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Sep. 30, 2016
Schedule of Investments [Line Items]
Other assets, net	$ 877	$ 628
ViaCyte, Inc. [Member]
Schedule of Investments [Line Items]
Other assets, net	479	479
Other Noncurrent Assets [Member]
Schedule of Investments [Line Items]
Other assets, net	$ 398	$ 149

Other Assets - Additional Infor

Other Assets - Additional Information (Detail) - ViaCyte, Inc. [Member] $ in Millions	9 Months Ended
	Jun. 30, 2017USD ($)
Schedule of Investments [Line Items]
Equity method investment	$ 5.3
Other than temporary impairment loss on investment	4.8
Cost method of investment	$ 0.5
Maximum [Member]
Schedule of Investments [Line Items]
Company's ownership percentage	1.00%

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization expense	$ 0.6	$ 0.8	$ 1.9	$ 1.9

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Jun. 30, 2017	Sep. 30, 2016
Intangible Assets [Line Items]
Definite-lived intangible assets, Accumulated Amortization	$ (10,605)	$ (8,604)
Intangible assets, Gross Carrying Amount	31,835	31,129
Intangible assets, Net	$ 21,230	$ 22,525
Customer Lists and Relationships [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	8 years 10 months 24 days	8 years 10 months 24 days
Definite-lived intangible assets, Gross Carrying Amount	$ 17,888	$ 17,692
Definite-lived intangible assets, Accumulated Amortization	(7,349)	(6,123)
Definite-lived intangible assets, Net	$ 10,539	$ 11,569
Core Technology [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	8 years	8 years
Definite-lived intangible assets, Gross Carrying Amount	$ 530	$ 530
Definite-lived intangible assets, Accumulated Amortization	$ (530)	$ (530)
Developed Technology [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	10 years 9 months 18 days	11 years 9 months 18 days
Definite-lived intangible assets, Gross Carrying Amount	$ 9,216	$ 8,724
Definite-lived intangible assets, Accumulated Amortization	(1,247)	(618)
Definite-lived intangible assets, Net	$ 7,969	$ 8,106
Non-compete [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	5 years	5 years
Definite-lived intangible assets, Gross Carrying Amount	$ 230	$ 230
Definite-lived intangible assets, Accumulated Amortization	(92)	(58)
Definite-lived intangible assets, Net	$ 138	$ 172
Patents and Other [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	16 years 6 months	16 years 6 months
Definite-lived intangible assets, Gross Carrying Amount	$ 2,321	$ 2,321
Definite-lived intangible assets, Accumulated Amortization	(1,387)	(1,275)
Definite-lived intangible assets, Net	934	1,046
Definite-Lived Intangible Assets [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Gross Carrying Amount	30,185	29,497
Definite-lived intangible assets, Accumulated Amortization	(10,605)	(8,604)
Definite-lived intangible assets, Net	19,580	20,893
In-Process Research and Development [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net	1,004	987
Trademarks and Trade Names [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net	$ 646	$ 645

Intangible Assets - Estimated A

Intangible Assets - Estimated Amortization Expense (Detail) $ in Thousands	Jun. 30, 2017USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Remainder of 2017	$ 699
2,018	2,606
2,019	2,606
2,020	2,430
2,021	2,291
2,022	$ 2,251

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Sep. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	$ 26,791	$ 26,555

Goodwill - Schedule Of Carrying

Goodwill - Schedule Of Carrying Amount of Goodwill by Segment (Detail) $ in Thousands	9 Months Ended
	Jun. 30, 2017USD ($)
Goodwill [Line Items]
Balance as of September 30, 2016	$ 26,555
Currency translation adjustment	236
Balance as of June 30, 2017	26,791
In Vitro Diagnostics [Member]
Goodwill [Line Items]
Balance as of September 30, 2016	8,010
Balance as of June 30, 2017	8,010
Medical Device [Member]
Goodwill [Line Items]
Balance as of September 30, 2016	18,545
Currency translation adjustment	236
Balance as of June 30, 2017	$ 18,781

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 948	$ 830	$ 2,620	$ 2,729
Product costs [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	19	4	69	12
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	139	101	387	220
Selling, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 790	$ 725	$ 2,164	$ 2,497

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Stock-Based Compensation Activity [Line Items]
Unrecognized compensation costs related to non-vested awards	$ 5,300,000		$ 5,300,000
Weighted average period for recognition of compensation costs related to non-vested awards			2 years 2 months 12 days
Performance share awards fully expensed	$ 2,000,000		$ 2,000,000
Weighted average per share fair value of stock options	$ 7.22	$ 6.49	$ 7.57	$ 6.85
Dividend yield	0.00%	0.00%	0.00%	0.00%
Vesting period						3 years	3 years
Stock compensation expenses recognized	$ 948,000	$ 830,000	$ 2,620,000	$ 2,729,000
Total pre-tax intrinsic value of options exercised		400,000		1,700,000
Fiscal 2015 (2015 - 2017) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year			2,015
Performance period end year			2,017
Fiscal 2016 (2016 - 2018) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year			2,016
Performance period end year			2,018
Fiscal 2017 (2017 - 2019) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year			2,017
Performance period end year			2,019
Scenario Forecast [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period					3 years
Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Total pre-tax intrinsic value of options exercised	100,000		$ 100,000
Performance Level [Member] | Minimum [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage			20.00%
Performance Level [Member] | Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Performance share awards, estimated vesting percentage			200.00%
Nonqualified Stock Options [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	300,000	300,000	$ 900,000	900,000
Nonqualified Stock Options [Member] | Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock option exercisable on a pro-rata basis			1 year
Nonqualified Stock Options [Member] | Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period			4 years
Nonqualified Stock Options [Member] | Minimum [Member] | Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock option expiration term upon expiration of employment or service			7 years
Nonqualified Stock Options [Member] | Maximum [Member] | Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock option expiration term upon expiration of employment or service			10 years
Nonqualified Stock Options [Member] | Vesting Anniversary [Member] | Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage			25.00%
Restricted Stock Awards
Stock-Based Compensation Activity [Line Items]
Restricted stock expense	100,000	100,000	$ 400,000	200,000
Performance Shares [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	400,000	300,000	$ 1,000,000	1,300,000
Issuance of shares			38,505
Performance Shares [Member] | Fiscal 2015 (2015 - 2017) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded							$ 900,000
Performance Shares [Member] | Fiscal 2016 (2016 - 2018) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded						$ 1,300,000
Performance Shares [Member] | Scenario Forecast [Member] | Fiscal 2017 (2017 - 2019) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded					$ 1,200,000
Performance Shares [Member] | Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Issuance of shares			78,606
Employee Stock Purchase Plan [Member]
Stock-Based Compensation Activity [Line Items]
Annual compensation withheld, maximum limit			$ 25,000
Employee Stock Purchase Plan [Member] | Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	$ 100,000	100,000	$ 100,000	100,000
Common stock authorized, shares	600,000		600,000
Annual compensation withheld			10.00%
Employee contributions	$ 100,000		$ 100,000			$ 100,000
Restricted Stock Units (RSUs) [Member] | 2009 Equity Incentive Plan [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized			$ 200,000	$ 100,000
Number of stock units awarded			16,004	18,877
Number of stock units forfeited			446
Number of stock units outstanding	44,440		44,440			32,101
Number of stock units outstanding estimated fair value			$ 1,300,000			$ 900,000
Restricted Stock Units (RSUs) [Member] | Maximum [Member] | 2009 Equity Incentive Plan [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	$ 100,000	100,000
Deferred Stock Units [Member] | 2009 Equity Incentive Plan [Member] | Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized			$ 100,000	$ 100,000
Number of stock units awarded			2,953	6,646
Number of stock units outstanding	24,030		24,030			21,077
Number of stock units outstanding estimated fair value			$ 700,000			$ 600,000
Deferred Stock Units [Member] | Maximum [Member] | 2009 Equity Incentive Plan [Member] | Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	$ 100,000	$ 100,000
Number of stock units outstanding estimated fair value			$ 100,000	$ 100,000

Stock-based Compensation - Assu

Stock-based Compensation - Assumptions Used in Stock Option Plans (Detail)	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rates	1.80%	1.30%	1.70%	1.90%
Expected life (years)	4 years 8 months 12 days	4 years 8 months 12 days	4 years 7 months 6 days	4 years 7 months 6 days
Expected volatility	33.30%	35.20%	34.30%	36.80%
Dividend yield	0.00%	0.00%	0.00%	0.00%

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Fair Value at the Date of Grant (Detail)	9 Months Ended
	Jun. 30, 2017shares
Fiscal 2015 (2015 - 2017) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	8,440
Target Shares	42,199
Maximum Shares	84,398
Fiscal 2016 (2016 - 2018) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	13,268
Target Shares	66,338
Maximum Shares	132,676
Fiscal 2017 (2017 - 2019) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	10,437
Target Shares	52,185
Maximum Shares	104,370

Revolving Credit Facility - Add

Revolving Credit Facility - Additional Information (Detail) - Revolving Credit Facility [Member] - USD ($)	Nov. 02, 2016	Jun. 30, 2017
Line Of Credit Facility [Line Items]
Revolving credit facility amount	$ 30,000,000
Credit facility fee percentage	0.15%
Line of credit facility expiration month and year		2019-11
Debt outstanding		$ 0
Minimum [Member]
Line Of Credit Facility [Line Items]
Credit facility interest rate	1.00%
Maximum [Member]
Line Of Credit Facility [Line Items]
Credit facility interest rate	1.75%
Multi-currency Overdraft Facility [Member] | Ireland
Line Of Credit Facility [Line Items]
Line of credit facility additional borrowing capacity	$ 5,000,000
Credit facility incremental of additional borrowings	5,000,000
Multi-currency Overdraft Facility [Member] | Maximum [Member] | Ireland
Line Of Credit Facility [Line Items]
Line of credit facility additional borrowing capacity	$ 20,000,000

Net Income Per Share Data - Den

Net Income Per Share Data - Denominator for Computation of Basic and Diluted Net Income Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Abstract]
Net income available to common shareholders	$ 720	$ 3,934	$ 3,526	$ 7,408
Basic weighted average shares outstanding	13,155	12,995	13,190	12,969
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares	230	289	214	234
Diluted weighted average shares outstanding	13,385	13,284	13,404	13,203

Net Income Per Share Data - Add

Net Income Per Share Data - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Nov. 05, 2014
Earnings Loss Per Share [Line Items]
Weighted average diluted shares outstanding excluded outstanding stock options	100,000	300,000	100,000	200,000
Common stock repurchased, shares	169,868
Stock repurchased average price per share	$ 23.78
Common stock repurchased	$ 4,000,000
Amount available for future repurchases under the current authorization	$ 26,000,000		$ 26,000,000
Accelerated Share Repurchase Program [Member]
Earnings Loss Per Share [Line Items]
Maximum payments for repurchase of common stock					$ 30,000,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2016
Income Tax Disclosure [Line Items]
Income tax provisions	$ 533,000	$ 2,926,000	$ 3,315,000	$ 5,440,000
Effective tax rates	42.50%	42.80%	48.50%	42.30%
U.S. federal statutory tax rate	35.00%	35.00%	35.00%	35.00%
State income tax reserve reversals related to statutory filing			$ 200,000
Unrecognized tax benefits excluding interest and penalties that would impact effective tax rate	$ 1,200,000		1,200,000		$ 1,200,000
Undistributed earnings in foreign subsidiaries	$ 0		0		$ 0
Expiring Stock Option Awards [Member]
Income Tax Disclosure [Line Items]
Discrete tax expense			$ 300,000

Segment and Geographical Info58

Segment and Geographical Information - Additional Information (Detail)	9 Months Ended
	Jun. 30, 2017Segment
Segment Reporting [Abstract]
Number of operating segments	2

Segment and Geographical Info59

Segment and Geographical Information - Segment Revenue, Operating Income and Depreciation and Amortization (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting Information [Line Items]
Revenue	$ 17,790	$ 19,972	$ 53,054	$ 53,212
Operating income	1,743	6,597	6,688	12,776
Depreciation and amortization	1,405	1,406	4,006	3,703
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income	3,633	8,346	12,549	18,123
Operating Segments [Member] | Medical Device [Member]
Segment Reporting Information [Line Items]
Revenue	12,778	15,654	39,260	39,500
Operating income	1,403	6,673	6,627	12,825
Depreciation and amortization	1,132	982	3,180	2,440
Operating Segments [Member] | In Vitro Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	5,012	4,318	13,794	13,712
Operating income	2,230	1,673	5,922	5,298
Depreciation and amortization	103	222	309	647
Corporate [Member]
Segment Reporting Information [Line Items]
Operating income	(1,890)	(1,749)	(5,861)	(5,347)
Depreciation and amortization	$ 170	$ 202	$ 517	$ 616

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	9 Months Ended
	Jun. 30, 2017USD ($)€ / $	Jun. 30, 2017EUR (€)
Commitments And Contingencies [Line Items]
License agreement commencement date	2006-03	2006-03
Annual minimum payments for licenses	$ 228,000	€ 200,000
Exchange rate relating to license payment | € / $	1.1409
Future minimum payments associated with license | $	$ 2,300,000
Patents [Member]
Commitments And Contingencies [Line Items]
Patent expiry date	2027-09	2027-09